Included in the formulation
АТХ:L.04.A.C.10 Secukinumab
Pharmacodynamics:The monoclonal antibody IgG selectively binds the cytokine of interleukin 17A (IL-17A), which stimulates the immune and inflammatory responses in the formation of a psoriatic plaque.
Pharmacokinetics:After subcutaneous administration, the maximum concentration in the blood plasma is reached after 6 days.
Metabolism in the blood plasma to peptides and amino acids.
The half-life is 30 days. Elimination by the kidneys.
Indications:It is used for the treatment of psoriasis, psoriatic arthritis, ankylosing spondylitis.
XII.L40-L45.L40 Psoriasis
XIII.M45-M49.M45 Ankylosing spondylitis
XII.L40-L45.L40.5 Psoriasis arthropathic (M07.0-M07.3 *, M09.0 *)
Contraindications:Acute infectious diseases, age under 18 years, individual intolerance.
Carefully:Crohn's disease, tuberculosis.
Pregnancy and lactation:Recommendations for FDA - Category B. It is used in pregnancy and lactation.
Dosing and Administration:Subcutaneously, 300 mg once every 2-3 weeks; starting from the 8th week - 300 mg once a month.
The highest daily dose: 300 mg.
The highest single dose: 300 mg.
Side effects:Respiratory system: nasopharyngitis.
Hematopoietic system: neutropenia.
Digestive system: diarrhea.
Dermatological reactions: hives.
Allergic reactions.
Overdose:Cases of overdose are not described.
Treatment is symptomatic.
Interaction:Clinically significant interactions are not described.
Special instructions:
In the treatment and within 6 months after its end It is not recommended to vaccinate with live vaccines.